The approval of the clinical trial application in Moldova is a significant milestone for Precision BioSciences, as it is the first in vivo gene editing program for chronic hepatitis B to enter global clinical trials. This development is likely to boost investor confidence and positively impact the stock price in the short term, especially with the upcoming investor event to discuss safety data and trial plans.